Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Legend Biotech Corp. (LEGN) PT Raised to $83 at Cantor Fitzgerald
November 13, 2024 7:21 AM ESTCantor Fitzgerald analyst Rick Bienkowski raised the price target on Legend Biotech Corp. (NASDAQ: LEGN) to $83.00 (from $82.00) while maintaining a Overweight rating.
The analyst comments "The debate over anito-cel's (ACLX, OW) ASH abstract data overshadowed much of the 3Q24 LEGN earnings call, with management vigorously arguing in favor of Carvykti's efficacy and safety profile. We published on anito-cel's abstract... More
